FDA approves Epizyme’s treatment for epithelioid sarcoma

Epizyme (NASDAQ:EPZM) says the Food and Drug Administration granted accelerated approval of its Tazverik (tazemetostat) treatment for the patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma, a rare, slow-growing type of cancer.

The company says continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Tazverik, Epizyme’s lead drug candidate, also is in multiple clinical trials for other types of cancer including follicular lymphoma, which is under review by the FDA.

https://seekingalpha.com/news/3534219-fda-approves-epizymes-treatment-for-epithelioid-sarcoma